Liver Disease News and Research

RSS

The liver is one of the largest solid organs of the body. It is located in the upper right part of the abdomen. Most of the organ lies under cover of the rib cage.

Nutrient "floodgate" protects against inflammatory immune response

After every meal, the body must prevent the immune system from launching an all-out fight against food.

4 May 2007

HCV patients survival after liver transplantation is not improving

For liver transplant recipients without hepatitis C (HCV), survival has improved over time.

4 May 2007

Racial disparities in treatment of patients with cirrhosis and complications of portal hypertension

African-American and Hispanic patients hospitalized for complications of portal hypertension were less likely to undergo a palliative shunt, prompt endoscopy, or liver transplantation compared to white patients, according to a new study in the May issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD).

2 May 2007

Liver stiffness indicates severe portal hypertension in patients with hepatitis C-related cirrhosis

Measuring liver stiffness using transient elastography can predict severe portal hypertension in patients with hepatitis C-related cirrhosis, according to a new study in the May issue of Hepatology, the official journal of the American Association for the Study of Liver Diseases (AASLD).

2 May 2007

New test for liver disease

A researcher at the Stanford University School of Medicine has helped confirm the reliability of a new test for liver disease that is ushering in the long-promised era of personalized medicine based on each individual's genetic makeup.

30 Apr 2007

Link found between bile duct obstruction and bile duct cancer

When bile duct cancer cells were placed in the liver of animals with bile duct obstruction, they grew more rapidly than identical cells placed in animals without bile duct obstruction.

30 Apr 2007

Liver center leading record number of studies to tackle hepatitis C

While many research institutions are suffering from funding cuts, Drs. Bruce R. Bacon and Adrian M. Di Bisceglie are chugging away with their usual tenacity.

27 Apr 2007

Schering-Plough announces ZETIA spproved in Japan

Schering-Plough Corporation has announced that Schering-Plough K.K., the company's country operation in Japan, has received marketing approval for ZETIA (ezetimibe), a novel cholesterol-lowering agent that inhibits the absorption of cholesterol in the intestine.

20 Apr 2007

Geisinger Health System launches study on obesity and related liver problem

Relying on one of the largest collections of liver tissue samples ever acquired by a single organization, Geisinger Health System researchers have embarked on a massive study of one of the fastest growing liver problems.

17 Apr 2007

New drug therapy zaps hepatitis C in 12 weeks

Trials of new hepatitis C drug suggest sufferers could be cleared of the virus within 12 weeks of treatment.

16 Apr 2007

GlaxoSmithKline initiates study of PROMACTA in chronic idiopathic thrombocytopenic purpura

GlaxoSmithKline has announced the initiation of a global, open-label, single group trial that will assess the efficacy, safety and tolerability of PROMACTA (eltrombopag olamine) in patients previously treated for chronic idiopathic thrombocytopenic purpura (ITP).

15 Apr 2007

Hepatitis C virus can block other hepatitis C variants from infecting the same cell

There's infection and then there's superinfection - when a cell already infected by a virus gets a second viral infection. But some viruses don't like to share their cells.

5 Apr 2007

NAFLD fibrosis score helps predict advanced fibrosis in patients with nonalcoholic fatty liver disease

Certain routine demographic, clinical, and laboratory values can be used to identify advanced fibrosis in patients with nonalcoholic fatty liver disease (NAFLD).

4 Apr 2007

Critical receptor in liver regeneration identified

In studies in mouse models, researchers at the University of California, San Diego (UCSD) School of Medicine have found that a cellular receptor involved in triggering cell death is also a necessary component of tissue repair and regeneration immediately following liver injury.

2 Apr 2007

New target for removing unwanted ammonia from the body

Thousands of people with liver and kidney disease die every year from too much ammonia in their blood, and scientists from the United States and Japan have found a possible solution.

2 Apr 2007

Growing number of young people have fatty liver disease

Indiana University School of Medicine researchers are taking a closer look at a disease whose incidence is rising as obesity in children increases.

15 Mar 2007

Lactulose improves quality of life in patients with cirrhosis who have minimal hepatic encephalopathy

A study on patients with cirrhosis who had minimal hepatic encephalopathy (MHE), a condition in which behavioral, psychological and neurological changes are associated with advanced liver disease, found that cognitive function and health related quality-of-life improved when they took lactulose. Lactulose is a drug used to help eliminate toxins such as ammonia that are normally cleared by the liver.

5 Mar 2007

The model for end-stage liver disease

A review of the studies on the Model for End-Stage Liver Disease (MELD) found that it is an accurate predictor of survival of patients with a variety of liver diseases, is particularly useful in allocating organs for liver transplants, and can also be used to help determine the course of treatment in certain cases. However, it is possible to improve the accuracy of the model and efforts at refining will continue.

5 Mar 2007

Latest food scare in the U.S. hits Hollywood party scene

Hollywood's celebrities may have been exposed to the hepatitis A virus at one of 13 catered events, in particular a Sports Illustrated's swimsuit party.

28 Feb 2007

Key protein - claudin-1- for hepatitis C virus entry identified

For as many as 200 million people worldwide infected with hepatitis C, a leading cause of chronic liver disease, treatment options are only partially effective. But new research by Rockefeller University scientists points to a potential new target for better drugs: a key protein that resides in human liver cells that hepatitis C requires for entry.

27 Feb 2007